File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Placebo-controlled trial of recombinant α2-interferon in Chinese HBsAg-carrier children

TitlePlacebo-controlled trial of recombinant α2-interferon in Chinese HBsAg-carrier children
Authors
Issue Date1987
PublisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/lancet
Citation
Lancet, 1987, v. 2 n. 8564, p. 877-880 How to Cite?
Abstract24 Chinese children aged 1.5-5 years and positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), hepatitis B virus DNA polymerase (HBV DNAp), and HBV DNA on at least three occasions in the 6 months before the trial were randomised to receive either vitamin B complex or intramuscular recombinant α2-interferon (r-IFN) ('Roferon') 10 x 106 IU/m2 thrice weekly for 12 weeks. In all 12 subjects receiving r-IFN, HBV DNAp and HBV DNA levels fell during the course of r-IFN injections. Within 4 weeks of cessation of r-IFN injection, the HBV DNAp and HBV DNA returned to pre-trial levels except in 2 subjects, in whom loss of HBV DNAp and HBV DNA was sustained for up to 18 months from onset of the trial. 1 child lost HBeAg at 18 months, 2 of the 12 children in the placebo group also had a sustained loss of HBV DNAp and HBV DNA during the 18 months, with 1 child losing HBeAg at 18 months. All 24 subjects remained positive for HBsAg. r-IFN produced very slight side-effects except for pyrexia and the 'flu' syndrome, both of which showed rapid tachyphylaxis. In the dose given r-IFN was safe but had no long-term beneficial effects on HBsAg carriage in Chinese children.
Persistent Identifierhttp://hdl.handle.net/10722/161737
ISSN
2015 Impact Factor: 44.002
2015 SCImago Journal Rankings: 14.638
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLai, CLen_US
dc.contributor.authorLin, HJen_US
dc.contributor.authorYeoh, EKen_US
dc.contributor.authorLok, ASFen_US
dc.contributor.authorWu, PCen_US
dc.contributor.authorYeung, CYen_US
dc.date.accessioned2012-09-05T05:14:33Z-
dc.date.available2012-09-05T05:14:33Z-
dc.date.issued1987en_US
dc.identifier.citationLancet, 1987, v. 2 n. 8564, p. 877-880en_US
dc.identifier.issn0140-6736en_US
dc.identifier.urihttp://hdl.handle.net/10722/161737-
dc.description.abstract24 Chinese children aged 1.5-5 years and positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), hepatitis B virus DNA polymerase (HBV DNAp), and HBV DNA on at least three occasions in the 6 months before the trial were randomised to receive either vitamin B complex or intramuscular recombinant α2-interferon (r-IFN) ('Roferon') 10 x 106 IU/m2 thrice weekly for 12 weeks. In all 12 subjects receiving r-IFN, HBV DNAp and HBV DNA levels fell during the course of r-IFN injections. Within 4 weeks of cessation of r-IFN injection, the HBV DNAp and HBV DNA returned to pre-trial levels except in 2 subjects, in whom loss of HBV DNAp and HBV DNA was sustained for up to 18 months from onset of the trial. 1 child lost HBeAg at 18 months, 2 of the 12 children in the placebo group also had a sustained loss of HBV DNAp and HBV DNA during the 18 months, with 1 child losing HBeAg at 18 months. All 24 subjects remained positive for HBsAg. r-IFN produced very slight side-effects except for pyrexia and the 'flu' syndrome, both of which showed rapid tachyphylaxis. In the dose given r-IFN was safe but had no long-term beneficial effects on HBsAg carriage in Chinese children.en_US
dc.languageengen_US
dc.publisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/lanceten_US
dc.relation.ispartofLanceten_US
dc.subject.meshCarrier State - Therapyen_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshClinical Trials As Topicen_US
dc.subject.meshDna, Viral - Analysisen_US
dc.subject.meshDna-Directed Dna Polymerase - Analysisen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHepatitis B - Therapyen_US
dc.subject.meshHepatitis B Surface Antigens - Analysisen_US
dc.subject.meshHepatitis B Virus - Enzymologyen_US
dc.subject.meshHong Kongen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshInjections, Intramuscularen_US
dc.subject.meshInterferon Type I - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshMaleen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRandom Allocationen_US
dc.subject.meshRecombinant Proteins - Administration & Dosage - Therapeutic Useen_US
dc.titlePlacebo-controlled trial of recombinant α2-interferon in Chinese HBsAg-carrier childrenen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid2889081-
dc.identifier.scopuseid_2-s2.0-0023616670en_US
dc.identifier.volume2en_US
dc.identifier.issue8564en_US
dc.identifier.spage877en_US
dc.identifier.epage880en_US
dc.identifier.isiWOS:A1987K475600003-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridLin, HJ=7405571292en_US
dc.identifier.scopusauthoridYeoh, EK=35427828500en_US
dc.identifier.scopusauthoridLok, ASF=35379868500en_US
dc.identifier.scopusauthoridWu, PC=7403119323en_US
dc.identifier.scopusauthoridYeung, CY=7201354144en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats